VCM
TCRX icon

Voleon Capital Management’s TScan Therapeutics TCRX Stock Holding History

Voleon Capital Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-47,879
Closed -$87.1K – 1015
2025
Q3 		$87.1K Buy
+47,879
New +$84.8K ﹤0.01% 863

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Voleon Capital Management's TCRX Position: Q4 2025 in Review

Voleon Capital Management sold out of TScan Therapeutics (TCRX) in Q4 2025, closing a stake of 47,879 shares — an estimated $87.1K sold.

Voleon Capital Management first reported a position in TCRX in Q3 2025 and held it in 1 quarter. The position peaked at $87.1K in Q3 2025. 61 funds tracked by Wall St. Rank hold TCRX as of Q4 2025.

  • Voleon Capital Management reported no remaining TScan Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Voleon Capital Management sold 47,879 TScan Therapeutics shares in Q4 2025, an estimated $87.1K.
  • Voleon Capital Management first reported a position in TScan Therapeutics in Q3 2025 and held it in 1 quarter.
  • Voleon Capital Management's TScan Therapeutics position peaked at $87.1K in Q3 2025.
  • 61 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2025.

Based on Voleon Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.